Artia Global Partners LP Takes $2.82 Million Position in Roivant Sciences Ltd. $ROIV

Artia Global Partners LP bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 129,800 shares of the company’s stock, valued at approximately $2,817,000.

A number of other institutional investors have also modified their holdings of ROIV. UBS Group AG increased its holdings in shares of Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after acquiring an additional 15,645,836 shares during the period. Morgan Stanley increased its holdings in shares of Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after acquiring an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Roivant Sciences by 365.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after acquiring an additional 8,621,567 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Roivant Sciences by 11,507.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after acquiring an additional 6,877,348 shares during the period. Finally, Norges Bank acquired a new position in shares of Roivant Sciences in the 4th quarter valued at $112,750,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CAO Jennifer Humes sold 13,538 shares of the business’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the sale, the chief accounting officer directly owned 84,191 shares in the company, valued at $2,388,498.67. The trade was a 13.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $30.27, for a total transaction of $6,054,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares in the company, valued at $48,827,417.01. This represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 703,312 shares of company stock worth $20,805,883. Corporate insiders own 10.80% of the company’s stock.

Roivant Sciences Price Performance

NASDAQ:ROIV opened at $31.20 on Thursday. The firm’s fifty day moving average price is $29.10 and its 200 day moving average price is $26.22. Roivant Sciences Ltd. has a 1-year low of $10.70 and a 1-year high of $32.79. The firm has a market cap of $22.44 billion, a price-to-earnings ratio of -52.00 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. The company had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same period in the previous year, the firm earned ($0.29) EPS. As a group, analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of recent research reports. TD Cowen lifted their target price on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Citigroup lifted their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $33.59.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.